drug
(efgartigimod alfa + hyaluronidase (human recombinant))
Phase 3updated 6mo agoby $ARGX ARGENX SE
Phase 3community read0 votes
🐶 often sniffed alongside
top 3all catalysts(0)
nothing on the calendar yet
News(8)
- Argenx falls as Sjögren’s setback offsets celiac drug progressA monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ‘blockbuster expansion opportunity’ for Vyvgart.biopharma_dive · 1mo ago
- Argenx shutters Sjogren's study, losing blockbuster expansion opportunity for VyvgartArgenx shares have fallen more than 13% after the surprise futility finding, which overshadowed a mid-stage celiac disease win for a separate asset acquired in the company’s $2.2 billion Forte Bios…biospace · 1mo ago
- Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal runA phase 2 celiac disease trial of argenx’s FB102 has hit its primary endpoint, delivering a boost to a drug candidate that the biotech acquired in its $2.2 billion takeover of Forte Biosciences.fiercebiotech · 1mo ago
- Big Pharma-backed Nuvig halts development of lead fusion protein in rare autoimmune diseaseBig Pharma-backed Nuvig Therapeutics has halted one of the two trials for its sole clinical asset after determining the program wouldn’t be able to advance quickly enough.fiercebiotech · 1mo ago
- 6 immunology targets to sustain a mammoth I&I marketJohnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…biospace · 1mo ago
- Argenx jumps on Phase 3 data for blockbuster VyvgartThe latest results give investors confidence in the drug's ability to be approved in another indication for which there are no approved treatments.biopharma_dive · 2mo ago
- Argenx declares Phase 3 win for Vyvgart Hytrulo in autoimmune myositisArgenx said Monday that Vyvgart Hytrulo passed a late-stage test in a family of rare autoimmune diseases, even though the drug missed the mark in a key patient subgroup. The subcutaneous drugendpoints · 2mo ago
- Argenx deepens immuno expertise with $2.2B Forte Biosciences buyThe star of the takeover is Forte Biosciences' investigational antibody therapy, FB102, which has shown early potential in vitiligo and celiac disease.biospace · 3mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that